Labels set triggers, not one universal panel
The labels separate ongoing diabetes monitoring from evaluation prompted by a risk, adverse reaction, or clinical suspicion. Other labs may matter because of a person’s underlying conditions or other medicines, but these sources do not establish a one-size-fits-all GLP-1 panel.
| Situation | What the sources say | Boundary |
|---|---|---|
| Diabetes control | Both labels say blood glucose should be monitored before starting and during treatment in patients with diabetes. [1] [2] | This does not create one testing schedule for every GLP-1 user. |
| Volume-depletion concern | Both labels call for renal-function monitoring when adverse reactions could lead to volume depletion, particularly during initiation and escalation; gastrointestinal reactions causing dehydration are the context. [1] [2] | Risk-triggered, not a universal kidney-test calendar. |
| Gallbladder suspicion | Wegovy says gallbladder studies and clinical follow-up are indicated if cholelithiasis is suspected; Zepbound says the same if cholecystitis is suspected. [1] [2] | Symptom- or suspicion-triggered, not routine screening. |
| Pancreatic enzymes | Both labels report amylase and lipase increases and state that their clinical significance is unknown without other signs or symptoms of pancreatitis. [1] [2] | An isolated enzyme rise is not self-interpreting. |
| Calcitonin / thyroid ultrasound | Both labels say routine serum calcitonin or thyroid-ultrasound monitoring is of uncertain value for early detection of medullary thyroid carcinoma. [1] [2] | The labels do not recommend it as a routine early-detection strategy. |
Why A1C timing is diabetes-specific
A1C reflects average glycemia over about two to three months. ADA 2026 diabetes-care guidance recommends assessing glycemic status at least twice yearly, and more often—for example, every three months—for people not at goals or with factors such as recent treatment changes, frequent or severe hypo- or hyperglycemia, or changes in health status. [3]
That is diabetes-care guidance, not a universal schedule for every person using a GLP-1 medicine. The individual plan still depends on the reason for treatment and the prescriber’s goals.
How to preserve a lab trend without interpreting it
Keep each result attached to its collection date, exact value, unit, and the reference range printed by that laboratory. MedlinePlus notes that laboratories may use different methods and reference ranges, so results from different laboratories are not directly comparable; using the same laboratory can help when looking for trends. [4]
Record preparation and context that are already known—such as whether fasting instructions were followed, medicines or supplements, eating or drinking, and strenuous exercise—because these can affect some tests. Preserve that context without inferring that it caused a result. [4]
A1C is an indirect measure of average glycemia over roughly two to three months. It does not show real-time glucose, glycemic variability, or hypoglycemia, and conditions that affect hemoglobin or red-cell turnover can affect its interpretation. [3]
| Record field | What to preserve |
|---|---|
| Test name | The test name as reported |
| Collection date and time | The specimen collection date and time |
| Exact value | The result copied exactly |
| Unit + lab reference range | The unit and the printed reference range from that laboratory |
| Lab name | The laboratory that produced the result |
| Context already known | Fasting status if instructed, medication or product timeline, and symptoms or health changes |
This is a handoff record for a prescriber, not an interpretation or recommendation.
What a clean protocol history contains
Tracking supplies context; it does not interpret a result. A clear record can keep the following information together for a prescriber:
- Indication and exact medication or product name
- Clinician-directed schedule and documented changes
- Injection dates and symptom timing
- Weight or progress trend
- Concurrent glucose-lowering medicines
- Lab dates and results copied exactly
- Questions to bring to the prescriber
Five questions to bring to a prescriber
- What is the goal of each lab in my plan?
- Is there a baseline result we are comparing against?
- What symptom or change would trigger an earlier check?
- How do my other glucose-lowering medicines change the monitoring plan?
- What result should prompt me to contact you?
Keep dates in context
Build a legible protocol history
Jabbit can log clinician-directed injection schedules, reminders, injection history, progress, and symptom timing so a prescriber sees dates in context. It does not interpret labs or select tests.
Track your clinician-directed plan in JabbitFrequently asked questions
Is there a standard GLP-1 blood panel?
No single panel is defined for everyone in the current Wegovy and Zepbound labels. Monitoring depends on diabetes status, other medicines, symptoms, risks, and the prescriber’s plan. [1] [2]
Do Wegovy and Zepbound require kidney tests for everyone?
The labels do not establish routine kidney testing for everyone. They call for renal-function monitoring when adverse reactions could lead to volume depletion, especially during initiation and escalation. [1] [2]
Should calcitonin be checked routinely?
Both labels state that routine serum calcitonin or thyroid-ultrasound monitoring is of uncertain value for early detection of medullary thyroid carcinoma. [1] [2]
What do higher amylase or lipase levels mean?
Both labels report increases and say their clinical significance is unknown without other signs or symptoms of pancreatitis. An isolated result is not self-interpreting. [1] [2]
How often is A1C checked?
ADA diabetes-care guidance recommends assessing glycemic status at least twice yearly, and more often—for example, every three months—for people not at goals or with factors such as recent treatment changes. This is diabetes guidance, not a universal GLP-1 schedule. [3]
Can I compare lab results from different laboratories?
Not reliably by the number alone. MedlinePlus notes that laboratories may use different methods and reference ranges, and reports include units. Keep each result with its lab, unit, and printed reference range; a prescriber can interpret whether a change is meaningful. [4]
Sources opened and checked
- [1]Current Wegovy labeling, DailyMed.
- [2]Current Zepbound labeling, DailyMed.
- [3]ADA Standards of Care in Diabetes—2026, Section 6.
- [4]MedlinePlus, How to Understand Your Lab Results.
All four sources were opened and checked on August 10, 2026.